Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non–small cell lung cancer
JA Engelman, PA Jänne - Clinical Cancer Research, 2008 - AACR
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors gefitinib and erlotinib are
effective therapies for non–small cell lung cancer patients whose tumors harbor somatic …
effective therapies for non–small cell lung cancer patients whose tumors harbor somatic …
Resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non–small cell lung cancer
PS Hammerman, PA Jänne, BE Johnson - Clinical cancer research, 2009 - AACR
Gefitinib and erlotinib are ATP competitive inhibitors of the epidermal growth factor receptor
(EGFR) tyrosine kinase and are approved around the world for the treatment of patients with …
(EGFR) tyrosine kinase and are approved around the world for the treatment of patients with …
Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non–small-cell lung cancers dependent on the epidermal growth factor receptor …
KSH Nguyen, S Kobayashi, DB Costa - Clinical lung cancer, 2009 - Elsevier
Abstract Most advanced Non–Small-cell lung cancers (NSCLCs) with activating epidermal
growth factor receptor (EGFR) mutations (exon 19 deletions or L858R) initially respond to …
growth factor receptor (EGFR) mutations (exon 19 deletions or L858R) initially respond to …
Mechanisms of resistance to EGFR TKIs and development of a new generation of drugs in non‐small‐cell lung cancer
T Kosaka, E Yamaki, A Mogi… - BioMed Research …, 2011 - Wiley Online Library
Gefitinib and erlotinib, which are epidermal growth factor receptor‐(EGFR‐) specific tyrosine
kinase inhibitors (TKIs), are widely used as molecularly targeted drugs for non‐small‐cell …
kinase inhibitors (TKIs), are widely used as molecularly targeted drugs for non‐small‐cell …
Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non–small-cell lung cancer
Ten percent of North American patients with non–small-cell lung cancer have tumors with
somatic mutations in the gene for the epidermal growth factor receptor (EGFR) …
somatic mutations in the gene for the epidermal growth factor receptor (EGFR) …
[HTML][HTML] Mechanisms of acquired resistance to first-and second-generation EGFR tyrosine kinase inhibitors
Patients with non-small-cell lung cancer (NSCLC) whose tumours harbour activating
mutations within the epidermal growth factor receptor (EGFR) frequently derive significant …
mutations within the epidermal growth factor receptor (EGFR) frequently derive significant …
Acquired resistance of lung adenocarcinoma to EGFR-tyrosine kinase inhibitors gefitinib and erlotinib
Y Xu, H Liu, J Chen, Q Zhou - Cancer biology & therapy, 2010 - Taylor & Francis
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib
and erlotinib, are the first targeted therapy drugs approved for the treatment of advanced non …
and erlotinib, are the first targeted therapy drugs approved for the treatment of advanced non …
Strategies for overcoming resistance to EGFR family tyrosine kinase inhibitors
G Giaccone, Y Wang - Cancer treatment reviews, 2011 - Elsevier
The first-generation epidermal growth factor receptor tyrosine kinase inhibitors erlotinib and
gefitinib have been incorporated into treatment paradigms for patients with advanced non …
gefitinib have been incorporated into treatment paradigms for patients with advanced non …
Uncommon epidermal growth factor receptor mutations in non-small cell lung cancer and their mechanisms of EGFR tyrosine kinase inhibitors sensitivity and …
E Massarelli, FM Johnson, HS Erickson, II Wistuba… - Lung Cancer, 2013 - Elsevier
Therapy targeted against the epidermal growth factor receptor (EGFR) has demonstrated
dramatic tumor responses and favorable clinical outcomes in a select group of non-small …
dramatic tumor responses and favorable clinical outcomes in a select group of non-small …
Reciprocal and Complementary Role of MET Amplification and EGFR T790M Mutation in Acquired Resistance to Kinase Inhibitors in Lung Cancer
K Suda, I Murakami, T Katayama, K Tomizawa… - Clinical cancer …, 2010 - AACR
Purpose: In epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy
for lung cancer patients, acquired resistance develops almost inevitably and this limits the …
for lung cancer patients, acquired resistance develops almost inevitably and this limits the …
相关搜索
- kinase inhibitors in lung cancer
- small cell lung cancer
- mechanisms of acquired resistance
- egfr tyrosine acquired resistance
- lung cancer egfr tkis
- lung adenocarcinoma acquired resistance
- egfr tyrosine kinase inhibitors
- acquired resistance kinase inhibitors
- lung cancer mechanisms of resistance
- lung adenocarcinoma kinase inhibitors
- lung adenocarcinoma egfr tyrosine
- mechanisms of resistance egfr tkis